RESPONSE TO ANTI-TUMOR NECROSIS FACTOR-A ANTIBODY IN CHILDREN WITH CROHN'S

克罗恩病儿童对抗肿瘤坏死因子抗体的反应

• 批准号: 7717498
• 负责人: Scott C. Denne
• 金额: --
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717498
• 关键词: Aftercare; Albumins; Amino Acids; Antibodies; Blood; Calorimetry; Catabolism; Cells; Child; Childhood; Clinical; Computer Retrieval of Information on Scientific Projects Database; Crohn' s disease; Diagnosis; Disease remission; Energy Metabolism; Fasting; Funding; Grant; Hematocrit procedure; Institution; Intestinal Neoplasms; Intravenous; Label; Laboratories; Lipids; Maintenance; Messenger RNA; Metabolism; Neoadjuvant Therapy; Physical Examination; Play; Proteins; Rate; Reporting; Research; Research Personnel; Resources; Rest; Role; Schedule; Sedimentation process; Serum; Serum Albumin; Source; Symptoms; Testing; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; United States National Institutes of Health; Visit; Week; feeding; human TNF protein; indexing; infliximab; lipid metabolism; oxidation; respiratory; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children with Crohn's disease are often malnourished at their initial diagnosis. Tumor necrosis factor-a (TNF-a) plays a pivotal role in Crohn's disease, as evidenced by increased serum TNF-a levels, intestinal TNF-a mRNA levels, and intestinal TNF-a secreting cells. Anti-tumor necrosis factor-a (anti-TNF-a) antibody (Infliximab) is an effective therapy for the induction and maintenance of clinical remission of Crohn's disease. The aim of this study is to quantify changes in protein and lipid metabolism, resting energy expenditure, and albumin synthesis in children with Crohn's disease before and after treatment with anti-TNF-a antibody. We hypothesize that this treatment will decrease protein and lipid catabolism, decrease resting energy expenditure, and increase albumin synthesis. Our hypotheses will be tested by administering intravenous labeled amino acids in the fasting and intravenously fed states on the morning each child is scheduled to receive anti-TNF-a antibody. Serial blood draws will allow for analysis of rates of protein and albumin metabolism. Indirect respiratory calorimetry will be conducted at the end of the fasting and fed portions of the study for analysis of resting energy expenditure and lipid oxidation. The Pediatric Crohn's Disease Activity Index, including subjective report of symptoms, physical examination findings, and three laboratory examinations (hematocrit, erythocyte sedimentation rate, and serum albumin), will be administered to each child during the visit. These children will then be studied in an identical manner two weeks later.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 克罗恩病的儿童在最初的诊断中通常会营养不良。 肿瘤坏死因子-A（TNF-A）在克罗恩病中起关键作用，这可以通过血清TNF-A水平，肠道TNF-A mRNA水平和肠道TNF-A分泌细胞的升高证明。 抗肿瘤坏死因子-A（抗TNF-A）抗体（英夫利昔单抗）是一种有效的疗法，可诱导和维持克罗恩病的临床缓解。 这项研究的目的是量化抗TNF-A抗体治疗前和治疗后克罗恩病儿童中蛋白质和脂质代谢，静止能量消耗和白蛋白合成的变化。 我们假设这种治疗方法将减少蛋白质和脂质分解代谢，减少静息能量消耗并增加白蛋白合成。 我们的假设将通过在禁食中静脉注射标记的氨基酸和静脉注射状态来测试我们的假设，每个孩子计划接受抗TNF-A抗体。 抽血将允许分析蛋白质和白蛋白代谢的速率。 间接呼吸量热法将在禁食结束时进行研究，并进行研究部分，以分析静息能量消耗和脂质氧化。 小儿克罗恩病活动指数，包括症状，体格检查结果和三项实验室检查（血细胞比容，红细胞，红细胞沉降率和血清白蛋白）的主观报告，在访问期间将向每个孩子施用。 然后，两周后将以相同的方式对这些孩子进行研究。